Cargando…
Receptor GP IIb/IIIa as an Indicator of Risk in Vascular Events
Type 2 diabetes causes a significant risk of cardiovascular diseases, leading to 70% of deaths in patients with diabetes. The effective treatment of diabetes significantly reduces the risk of requiring the involvement of specialists from various fields of medicine. This research aimed to assess the...
Autores principales: | Fiodorenko-Dumas, Żanna, Dumas, Ilias, Mastej, Krzysztof, Jakobsche-Policht, Urszula, Bittner, Jadwiga, Adamiec, Rajmund |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714900/ https://www.ncbi.nlm.nih.gov/pubmed/31185733 http://dx.doi.org/10.1177/1076029619845056 |
Ejemplares similares
-
The influences of selected clotting and fibrinolysis factors on survival of patients with kidney tumors – a prospective study
por: Tupikowski, Krzysztof, et al.
Publicado: (2021) -
Thrombocytopenia induced by glycoprotein (GP) IIb-IIIa antagonists: about two cases
por: Abdeladim, Salma, et al.
Publicado: (2021) -
Safety of bridging antiplatelet therapy with the gpIIb-IIIa inhibitor tirofiban after emergency stenting in stroke
por: Lee, John-Ih, et al.
Publicado: (2017) -
Association of Novel Advanced Glycation End-Product (AGE10) with Complications of Diabetes as Measured by Enzyme-Linked Immunosorbent Assay
por: Bronowicka-Szydełko, Agnieszka, et al.
Publicado: (2021) -
GP IIb/IIIa-Mediated Platelet Activation and Its Modulation of the Immune Response of Monocytes Against Candida albicans
por: Zheng, Lin, et al.
Publicado: (2021)